Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-868 PK/PD Study in Obesity and T2DM
NCT04973111Phase 1Completed
- Sponsor
- Carmot Therapeutics
- Start
- Jul 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of acmopatide in type 2 diabetes mellitus (T2DM) and obesity (3 arms), sponsored by Carmot Therapeutics. Primary endpoint: Change in insulin secretion rate and ambient glucose levels at 4 days. Started Jul 2021; status: completed.
02
Drugs
acmopatide
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT04973111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04973111.